Last reviewed · How we verify
Prevenar and Pneumo23
Prevenar and Pneumo23 are pneumococcal conjugate and polysaccharide vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae.
Prevenar and Pneumo23 are pneumococcal conjugate and polysaccharide vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults and children, Prevention of pneumococcal pneumonia and bacteremia.
At a glance
| Generic name | Prevenar and Pneumo23 |
|---|---|
| Also known as | Prevenar (heptavalent conjugated pneumococcal vaccine), Pneumo23 (23valent polysaccharide pneumococcal vaccine) |
| Sponsor | Hospital Universitari Son Dureta |
| Drug class | Vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Prevenar (pneumococcal conjugate vaccine) contains polysaccharide antigens from pneumococcal serotypes conjugated to a protein carrier, eliciting both T-cell dependent and antibody responses. Pneumo23 (pneumococcal polysaccharide vaccine) contains polysaccharide antigens from 23 pneumococcal serotypes that stimulate B-cell responses. Together, they provide complementary immunological coverage against invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease in adults and children
- Prevention of pneumococcal pneumonia and bacteremia
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or fatigue
- Headache
Key clinical trials
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (PHASE2, PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevenar and Pneumo23 CI brief — competitive landscape report
- Prevenar and Pneumo23 updates RSS · CI watch RSS
- Hospital Universitari Son Dureta portfolio CI